Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications
Sanjay Kalra, Ambika G. Unnikrishnan, Navneet Agrawal and Anupam K. Singh
Affiliation: Bharti Hospital, Kunjpura Road, Karnal, 132001, Haryana, India.
Keywords: Diabetes, Pharmacokinetics, placebo, DPP4 inhibitors, hepatic safety, incretins, linagliptin, oral hypoglycemics, multiple sclerosis, renal safety
The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. These agents may be used either as monotherapy for the treatment of type-2 diabetes or in combination with other anti-diabetic drugs. The present review highlights the use of linagliptin and other new (DPP-4) inhibitors in the management of type-2 diabetes. The review also highlights advantages, comparative pharmacokinetic, safety profile and other potential uses including potential newer indications of DPP-4 inhibitors and relevant patents. The other potential uses that are not restricted to diabetes include obesity, cardiovascular disease, neurological disease, hepatobiliary disease, wound healing, and other inflammatory illnesses.
Rights & PermissionsPrintExport